Adenocarcinoma of the Colon
36
5
5
19
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
13.9%
5 terminated out of 36 trials
79.2%
-7.3% vs benchmark
17%
6 trials in Phase 3/4
37%
7 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (36)
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
Liquid Biopsy in Early Colorectal Lesions
Ultrasonic Versus Conventional Clipping Hemostasis in Laparoscopic Colorectal Surgery
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
Intracorporeal Versus Extracorporeal Anastomosis In Laparoscopic Right Colon Resection
Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
Prospective Study of Oncologic Outcomes After Laparoscopic Modified Complete Mesocolic Excision for Non-metastatic Right Colon Cancer [PIONEER Study]
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
Human Intestinal Microbiome and Surgical Outcomes in Patients Undergoing Colorectal Cancer Surgery
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer